Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy

Eswari Dodagatta-Marri,Hsiao-Yen Ma,Benjia Liang,John Li,Dominique S Meyer,Szu-Ying Chen,Kai-Hui Sun,Xin Ren,Bahar Zivak,Michael D Rosenblum,Mark B Headley,Lauren Pinzas,Nilgun I Reed,Joselyn S Del Cid,Byron C Hann,Sharon Yang,Anand Giddabasappa,Kavon Noorbehesht,Bing Yang,Joseph Dal Porto,Tatsuya Tsukui,Kyle Niessen,Amha Atakilit,Rosemary J Akhurst,Dean Sheppard,Dominique S. Meyer,Michael D. Rosenblum,Mark B. Headley,Nilgun I. Reed,Joselyn S. Del Cid,Byron C. Hann,Rosemary J. Akhurst

DOI: https://doi.org/10.1016/j.celrep.2021.109309

IF: 8.8

2021-07-01

Cell Reports

Abstract:αvβ8 integrin, a key activator of transforming growth factor β (TGF-β), inhibits anti-tumor immunity. We show that a potent blocking monoclonal antibody against αvβ8 (ADWA-11) causes growth suppression or complete regression in syngeneic models of squamous cell carcinoma, mammary cancer, colon cancer, and prostate cancer, especially when combined with other immunomodulators or radiotherapy. αvβ8 is expressed at the highest levels in CD4+CD25+ T cells in tumors, and specific deletion of β8 from T cells is as effective as ADWA-11 in suppressing tumor growth. ADWA-11 increases expression of a suite of genes in tumor-infiltrating CD8+ T cells normally inhibited by TGF-β and involved in tumor cell killing, including granzyme B and interferon-γ. The <em>in vitro</em> cytotoxic effect of tumor CD8 T cells is inhibited by CD4+CD25+ cells, and this suppressive effect is blocked by ADWA-11. These findings solidify αvβ8 integrin as a promising target for cancer immunotherapy.

cell biology

What problem does this paper attempt to address?

The paper aims to address a key issue in tumor immunotherapy: how to enhance anti-tumor immune responses by targeting specific molecules, particularly for tumor types that respond poorly to existing immune checkpoint inhibitors such as PD-1 antibodies. Specifically, the study focuses on the role of integrin αvβ8 in the tumor microenvironment, especially its expression on CD4+CD25+ T cells and its ability to activate transforming growth factor-β (TGF-β), leading to tumor immune suppression.

The main findings of the paper include:
1. Integrin αvβ8 is highly expressed in the tumor microenvironment, particularly on CD4+CD25+ T cells, and can activate TGF-β, thereby inhibiting anti-tumor immune responses.
2. The use of a monoclonal antibody against αvβ8, ADWA-11, can block this process, promote tumor cell killing, and synergize with various immunomodulators or radiotherapy to induce long-term anti-tumor immunity.
3. In multiple tumor models, ADWA-11 not only inhibits tumor growth on its own but also significantly enhances the effects of other immunotherapies, especially when used in combination with PD-1 antibodies.
4. The study also found that CD8+ T cells play a critical role in the anti-tumor activity mediated by ADWA-11. ADWA-11 increases the expression of genes (such as granzyme B and interferon-γ) in these cells that are typically suppressed by TGF-β, enhancing their cytotoxicity and anti-tumor capabilities.

In summary, the paper proposes a new tumor immunotherapy strategy by targeting integrin αvβ8 to overcome tumor immune suppression, providing a theoretical basis for the development of new anti-cancer drugs.